Navigation Links
New Study Shows Long-Term Benefits for Patients with Pulmonary Arterial Hypertension
Date:4/24/2009

Results of a recent two-year study show promising long-term survival benefits for patients living with Pulmonary Arterial Hypertension (PAH), a progressive, life-threatening disease in which the small blood vessels in the lungs become scarred and narrowed causing the pressure in the pulmonary arteries to rise to dangerously high levels, putting a major strain on the heart.

Paris, FR (PRWEB) April 24, 2009 -- Results of a recent two-year study show promising long-term survival benefits for patients living with Pulmonary Arterial Hypertension (PAH), a progressive, life-threatening disease in which the small blood vessels in the lungs become scarred and narrowed causing the pressure in the pulmonary arteries to rise to dangerously high levels, putting a major strain on the heart.

During the last decade, there has been an explosion of novel, targeted treatment options, which have shown to increase quality of life and exercise tolerance in individuals living with PAH; however, research of these new treatments has focused mainly on outcomes other than survival in shorter term three-to-12 month studies.

Data will be presented tomorrow (Saturday, April 25) during the morning plenary session (9:15am local time) at the International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting at the Palais des Congres in Paris.

In tomorrow's ISHLT session, Professor Anne Keogh, Senior Transplant Cardiologist, St. Vincent's Hospital, Sydney, Australia, will discuss information specific to a study of longer-term effects of the oral treatment of Ambrisentan (ABS) in patients with PAH.

According to Professor Keogh, ABS doses of 5 mg or 10 mg per day were associated with 87 percent and 94 percent, respectively, two-year survival rates. Only one in five patients required additional drug therapy. Functional parameters and exercise tolerance were improved, and clinical worsening was reduced by ABS.

Discussion during this year's ISHLT meeting presents a unique forum for debating the latest advances in the management of patients with PAH. The annual ISHLT sessions provide the only formal international gathering where pulmonologists, cardiologists and cardiothoracic surgeons meet to share the very latest research and breakthroughs. PAH is a disease that is pertinent to the practices of all of these specialists, so it is of particular interest to ISHLT.

Treatment for PAH:

Ambrisentan, approved for use in patients with PAH, is a selective oral endothelin receptor antagonist, which means it blocks the action of endothelin, a very potent, naturally occurring vasoconstrictor that is capable of causing severe narrowing of the blood vessels. This treatment is intended to improve the symptoms, exercise tolerance and overall survival of PAH patients. Ambrisentan is believed to be associated with a lower risk of liver toxicity and fewer significant drug-to-drug interactions than other approved oral endothelin receptor antagonists.

Without treatment the prognosis for patients with PAH is worse than many cancers, yet until recently there has been no evidence that targeted oral treatments offer significant longer term survival benefits. The results of this two-year study are novel and will increase understanding of the role of such medications in PAH for physicians and patients.

About ISHLT:

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit organization with more than 2,700 members from over 45 countries dedicated to the advancement of the science and treatment of end-stage heart and lung diseases. For more information, visit www.ishlt.org.

###

Read the full story at http://www.prweb.com/releases/2009/04/prweb2355964.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Dont Lower Age for Cervical Cancer Test, Study Urges
2. Mayo clinic study finds gene bringing together animal and human research in alcoholism
3. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
4. Mayo Clinic Study Finds Gene Bringing Together Animal and Human Research in Alcoholism
5. Study links arm/hand swelling to number of lymph nodes removed during breast cancer surgery
6. New study argues for CT colonography as primary colon cancer screening test
7. Patients Had Fewer Infection Rates, Fewer Complications at Blue Distinction Centers for Bariatric Surgery(R), According to HealthCore Study
8. Pennsaid(R) Phase 3 study results to be published in leading international PAIN journal
9. Facet Solutions Completes 1 Year Follow-up on U.S. Pilot Study
10. BUSM study finds photographs of UV exposure can impact sunburns in preteens
11. Telesso initiates post-market head-to-head peripheral IV catheter study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... 2017 , ... Healthful Balance announces the national release of ... by Ed Stroup, was created to offer the highest quality vitamins and supplements ... service. Healthful Balance products can be purchased online through their website, or can ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of ... will be featuring DRTV campaigns regarding the topic of Beauty and Personal Care. ... version of themselves. What better way to commit to these changes than beginning with ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development ... to infusing high speed technology into the fabric of an entire community. A ... of healthcare and wellness in a yet-to-be-named, health focused campus. Leading this initiative ...
(Date:1/17/2017)... TX (PRWEB) , ... January 17, 2017 , ... Mirror ... have earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice ... named part of this elite group of providers. , Produced by Zeltiq, CoolSculpting ...
(Date:1/17/2017)... ... 17, 2017 , ... Peoples Health is pleased to announce ... Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more than ... to our provider network, and the addition will benefit our members in the ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 Interpace Diagnostics Group, Inc., (NASDAQ: ... diagnostic tests and pathology services for evaluating risks of ... dated January 13, 2017 from the NASDAQ Listing Qualifications ... the requirement of the NASDAQ Stock Market to maintain ... The letter noted that for the last ...
(Date:1/17/2017)... and Markets has announced the addition of the "The Top 200 ... ... profiles the leading 200 manufacturers and distributors of molecular diagnostics products worldwide. ... States and Europe to ... Profile information for each company in The Top 200 Molecular Diagnostics Companies ...
(Date:1/17/2017)... 17, 2017 Catherine ... http://www.touchneurology.com/articles/tailored-temperature-management-neurocritical-care ...      (Logo: ... European Neurological Review , ... Amey reports that despite standard care, temperatures ...
Breaking Medicine Technology: